Importantly, a recent research pointed out cyclin E overexpression is a mechanism of Trastuzumab resistance in HER2+ breast cancer patients. Thus, co-treatment of trastuzumab with CDK2 inhibitors may be a valid strategy.
Significantly, a recent study highlighted that elevated levels of cyclin E are a mechanism of resistance to Trastuzumab in HER2-positive breast cancer patients. Consequently, co-treatment with CDK2 inhibitors may be a viable approach.